Boston Partners Sells 1,794 Shares of Stryker Co. (NYSE:SYK)

Boston Partners lowered its stake in shares of Stryker Co. (NYSE:SYKFree Report) by 48.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,890 shares of the medical technology company’s stock after selling 1,794 shares during the quarter. Boston Partners’ holdings in Stryker were worth $566,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Keybank National Association OH raised its position in Stryker by 3.5% in the 3rd quarter. Keybank National Association OH now owns 27,823 shares of the medical technology company’s stock worth $7,603,000 after purchasing an additional 952 shares during the last quarter. Carnegie Capital Asset Management LLC increased its stake in shares of Stryker by 0.5% in the 4th quarter. Carnegie Capital Asset Management LLC now owns 96,241 shares of the medical technology company’s stock valued at $28,820,000 after buying an additional 497 shares during the period. CoreCap Advisors LLC raised its position in shares of Stryker by 3.9% during the fourth quarter. CoreCap Advisors LLC now owns 5,030 shares of the medical technology company’s stock worth $1,506,000 after acquiring an additional 191 shares during the last quarter. Consolidated Planning Corp acquired a new position in shares of Stryker during the fourth quarter valued at $205,000. Finally, Meritage Portfolio Management bought a new position in Stryker in the fourth quarter valued at about $569,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares in the company, valued at approximately $1,317,414. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 5.90% of the company’s stock.

Stryker Stock Performance

NYSE:SYK opened at $334.68 on Friday. The company has a market cap of $127.50 billion, a price-to-earnings ratio of 38.21, a PEG ratio of 2.61 and a beta of 0.91. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71. The stock has a fifty day moving average price of $342.20 and a 200-day moving average price of $322.20.

Stryker (NYSE:SYKGet Free Report) last released its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.36 by $0.14. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The firm had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. During the same period last year, the firm earned $2.14 EPS. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. As a group, equities analysts anticipate that Stryker Co. will post 11.94 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be issued a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date is Friday, June 28th. Stryker’s dividend payout ratio is presently 36.53%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SYK. Robert W. Baird upped their target price on shares of Stryker from $367.00 to $378.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Royal Bank of Canada increased their price target on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Evercore ISI lifted their price objective on Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Truist Financial increased their target price on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a research note on Wednesday, January 31st. Finally, UBS Group lifted their target price on Stryker from $339.00 to $351.00 and gave the stock a “neutral” rating in a report on Wednesday, May 1st. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $365.94.

Read Our Latest Stock Report on SYK

About Stryker

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Read More

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.